The convergence of life sciences and technology

New research from Bidwells, working with YouGov and Advanced Oxford, tracks the growing relationship between life science and technology companies

Convergence between life sciences and technology remains at an early stage, but the availability of patient data has expanded at an enormous pace, as has the data generated by life sciences companies through their R&D activities.  This data facilitates the application of technology, both at the drug discovery stage, but also in the advancement of the potential for personalisation of patient treatment.  Technical advances in AI and big data have supported the leveraging of data in tech driven drug discovery, clinical trials and patient management.  The pace of learning in these areas is building specialist knowledge in life science applications of technology, both in large companies, but particularly through the creation of start ups and spin-outs.

This new research examines the relationships, trends and examines the consequences for collaboration and co-location.

Read the report here

Recent news

Oxford Innovation Society: Venture-backed exits workshop

Oxford Innovation Society: Venture-backed exits workshop

Oxford Innovation Society (OIS) Business Bites are holding a workshop on 28th November all about venture backed exits.   Date: 28th November Time: 14:30 - 17:00 Venue: Oxford University Innovation, 55 Little Clarendon Street, Oxford A team of experts from James...

read more
Access to Finance 2025

Access to Finance 2025

Access to Finance 2025 is now open for registration!   After the success of the last five years, the event returns for its sixth year. The Science and Technology Facilities Council (STFC) in collaboration with Oxfordshire Greentech will bring together experts and...

read more
Oxford + Podcast Latest Episode

Oxford + Podcast Latest Episode

You can listen now to the latest episode from Oxford +, with George Robinson, founding partner of Oxford Investment Consultants. George talks about the unique challenges of investing in early-stage tech and biotech spinouts from Oxford University and brings incredible...

read more
Loading...